Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
MAXXF$1.80+0.06(+3.34%)Max Power Expands Scale of Saskatchewan Natural Hydrogen System With Lawson 5, Commences Follow-Up Well[12:46:13 AM ET]IBM$252.57-0.99(-0.39%)IBM Introduces Identity and Control for AI Agents, Securing Frontier Intelligence for the Enterprise At TechXchange 2026, IBM (NYSE: IBM) is announcing new capabilities to help developers, IT and security teams put AI agents to work across business...[12:01:00 AM ET]FCN$161.40+4.16(+2.65%)FTI Consulting Continues Growth of Middle East Tax Practice With Appointment of Sandeep Kumar as Senior Managing Director[12:00:00 AM ET]UUUU$7.56+0.04(+0.53%)Donald Rare Earth and Mineral Sands Project Achieves Major Government Financing Milestone Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) (ASX: EF2), a leading U.S.-based producer of rare earth elements ("REE"), uranium, and other...[11:20:00 PM ET]FUJIY$10.82+0.06(+0.56%)Fujifilm Introduces instax mini Evo 2™ Hybrid Instant Camera[10:00:00 PM ET]FUUFF$0.07+0.00(+0.14%)F3 Announces Grant of Stock Options and Restricted Share Units[9:33:00 PM ET]TXN$299.50+14.81(+5.20%)Texas Instruments prices $2.0 billion of investment grade notes Texas Instruments Incorporated (TI) (Nasdaq: TXN) today announced the pricing of four series of senior unsecured notes for an aggregate principal...[9:15:00 PM ET]CZZLF$0.240.00(0.00%)Cizzle Brands Accelerates U.S. National Exchange Listing Strategy to Drive Institutional Growth and Unlock Shareholder Value[8:30:00 PM ET]IMMFF$1.100.00(0.00%)Omni Bridgeway Makes Strong Start to FY27 with 3.9x MOIC on Completions and US$1 Billion Series II Final Close[8:19:28 PM ET]HRTX$0.30+0.00(+0.40%)Heron Therapeutics to Report Third Quarter 2026 Financial Results on Monday, November 9, 2026[8:09:52 PM ET]CPAC$12.77+0.04(+0.31%)Cementos Pacasmayo S.A.A. Announces Consolidated Results for Third Quarter 2026[8:04:00 PM ET]

ORKA · NASDAQ

Oruka Therapeutics, Inc.

$88.13 +10.13 (+12.64%)

Company overview

Oruka Therapeutics, Inc. is a biotechnology company that focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other immunology and inflammation (I&I) indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, California.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$5.8B
Employees
28
Headquarters
Menlo Park, MA
Website
orukatx.com
CEO
Lawrence Otto Klein
Listed
August 8, 1997
P/E
-36.87
Dividend yield
64.52%

Company financials

Revenue
$0.00
Gross profit
-$71,000
Operating income
-$133M
EBITDA
-$126M
Net income
-$116M
EPS
-$2.39
Total assets
$504M
Total debt
$1.8M
Earnings yield
-2.71%

Price chart

51.1467.8684.57101.28117.99
ORKA 1D NASDAQ O83.34H93.42L83.34C90.28+10.13 (+12.64%)Vol574.69K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
Ticker Type Headline Source Published
ORKAOruka Therapeutics, Inc. Stock news Oruka's ORKA-001 Delivers 61% Complete Skin Clearance in Phase IIb Psoriasis Study MarketBeat
ORKAOruka Therapeutics, Inc. Stock news Oruka Therapeutics, Inc. (ORKA) Discusses Interim EVERLAST-B Results for ORCA 001 in Plaque Psoriasis Transcript Seeking Alpha
ORKAOruka Therapeutics, Inc. Stock news Oruka Therapeutics Novel Biologic Outperforms Placebo in Psoriasis Trial Benzinga
ORKAOruka Therapeutics, Inc. Press release Oruka Therapeutics Announces Positive Week 16 Results for ORKA-001 from the Ongoing EVERLAST-B Trial in Moderate-to-Severe Psoriasis GlobeNewswire
ORKAOruka Therapeutics, Inc. Press release Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-B Trial on October 26, 2026 GlobeNewswire
ORKAOruka Therapeutics, Inc. Stock news Oruka Therapeutics: The Psoriasis Market Is Becoming A Barbell, And ORKA-001 Owns The Far End Seeking Alpha
ORKAOruka Therapeutics, Inc. Stock news ORKA Stock Down 5% Despite Positive Week 28 Psoriasis Efficacy Data Zacks Investment Research
ORKAOruka Therapeutics, Inc. Stock news Oruka Therapeutics Says Psoriasis Drug Shows Deepening Efficacy Benzinga
ORKAOruka Therapeutics, Inc. Press release Oruka Therapeutics Announces Positive Week 28 Data for ORKA-001 from the Ongoing EVERLAST-A Trial Showing Deepening of Responses Without Additional Dosing GlobeNewsWire
ORKAOruka Therapeutics, Inc. Press release Oruka Therapeutics to Attend the 2026 Morgan Stanley Global Healthcare Conference GlobeNewswire
ORKAOruka Therapeutics, Inc. Stock news ORKA Stock Up More Than 60% in 3 Months: Here's What You Should Know Zacks Investment Research
ORKAOruka Therapeutics, Inc. Stock news BlackRock Inc. Purchases Shares of 4,990,181 Oruka Therapeutics, Inc. $ORKA Defense World
ORKAOruka Therapeutics, Inc. Press release Oruka Therapeutics Appoints Todd Edwards as Chief Commercial Officer GlobeNewsWire
ORKAOruka Therapeutics, Inc. Press release Oruka Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update GlobeNewsWire
ORKAOruka Therapeutics, Inc. Stock news An Oruka Therapeutics (ORKA) Insider Sold 105,000 Shares Worth $6.2 Million Fool - Investing News
ORKAOruka Therapeutics, Inc. Press release Oruka Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update GlobeNewsWire
ORKAOruka Therapeutics, Inc. Stock news Why This Biotech Fund Increased Its Oruka Therapeutics Stake Amid a Staggering 500% Rally Fool - Investing News
ORKAOruka Therapeutics, Inc. Press release Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon™ Technology PRNewsWire
ORKAOruka Therapeutics, Inc. Stock news Oruka Therapeutics Touts “Category-Winning” ORKA-001 Data, Targets Once-Yearly Psoriasis Dosing Defense World
ORKAOruka Therapeutics, Inc. Press release Oruka Therapeutics Announces Pricing of Upsized $700 Million Underwritten Public Offering GlobeNewsWire
See more
FAQ

Questions about Oruka Therapeutics, Inc.

What does Oruka Therapeutics, Inc. do?
Oruka Therapeutics, Inc. is a biotechnology company that focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other immunology and inflammation (I&I) indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, California.
What is ORKA's market cap?
Oruka Therapeutics, Inc. (ORKA) is a listed stock with a live quote. The latest market cap on this page is $5.8B.
Where is Oruka Therapeutics, Inc. headquartered?
Oruka Therapeutics, Inc. is headquartered in Menlo Park, MA.
How do I get ORKA news from the API?
Call GET /v1/news?tickers=ORKA. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search the full archive in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees the full archive.
How far back does ORKA news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for ORKA, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees the full archive as headlines are ingested. A Free API key returns the last year. Pro keys search the full archive.
Is the ORKA price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 1,000 REST requests a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs